Can Fite Biopharma (CANF) Stock Price Up 14.5%

Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) shares rose 14.5% on Tuesday . The company traded as high as $2.10 and last traded at $1.90. Approximately 973,830 shares changed hands during mid-day trading, an increase of 269% from the average daily volume of 264,067 shares. The stock had previously closed at $1.66.

CANF has been the topic of a number of recent research reports. Maxim Group set a $7.00 target price on Can Fite Biopharma and gave the stock a “buy” rating in a research note on Monday, December 18th. HC Wainwright restated a “buy” rating on shares of Can Fite Biopharma in a research note on Tuesday, October 31st.

The company has a market capitalization of $25.30, a P/E ratio of 6.24 and a beta of 1.37.

ILLEGAL ACTIVITY WARNING: “Can Fite Biopharma (CANF) Stock Price Up 14.5%” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit